Document is current

Article History

Received: 27 August 2020

Accepted: 23 April 2021

First Online: 20 May 2021

Declarations

:

: All patients in this study provided written consent for participation under a protocol approved by local human research protections programs and institutional review boards at Dana-Farber Cancer Institute (DFCI#12-431) and Ohio State University (OSU#2018C0211). This study was conducted in accordance with the principles described in the Declaration of Helsinki.

: Not applicable.

: S.A.S. reported nonfinancial support from Bristol-Myers Squibb outside the submitted work. S.A.S. previously advised and has received consulting fees from Neon Therapeutics. S.A.S. reported nonfinancial support from Bristol-Myers Squibb, and equity in Agenus Inc., Agios Pharmaceuticals, Breakbio Corp., Bristol-Myers Squibb, Indiscine and Lumos Pharma, outside the submitted work. R.B.S. reported consulting Fees (e.g., advisory boards); Author; Roche, Merck, Eli Lilly. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus); Author; Eli Lilly, Libbs, Novartis, Pfizer, ROCHE, Bristol-Myers Squibb. G. Ha: Receipt of Intellectual Property Rights/Patent Holder; Broad Institute. VAA reported advisory boards for AGCT GmbH and BerMs Inc. S.M.T. reported consulting fees (e.g., advisory boards); AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung BioepsiVs. The remaining authors declare that they have no competing interests.